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OBJECTIVES We sought to evaluate the association between the extent of coronary artery disease (CAD)
and survival in patients with symptomatic heart failure (HF) and to create the most
prognostically powerful clinical definition of ischemic cardiomyopathy.
BACKGROUND An ischemic etiology of HF is known to be a predictor of adverse outcome; however, there
is no uniform definition for ischemic cardiomyopathy.
METHODS We assessed the clinical history and coronary anatomy of patients with symptomatic HF and
ejection fraction 40% undergoing diagnostic coronary angiography between 1986 and 1999
(n  1,921). Five classification schemes were tested to identify the most prognostically
powerful method for defining the extent of CAD and to develop the best definition of
ischemic cardiomyopathy for prognostic purposes.
RESULTS A more extensive CAD was independently associated with shorter survival. When the various
classification schemes were compared, a modified number-of-diseased-vessels classification,
in which patients with single-vessel disease and no prior history of revascularization or
myocardial infarction (MI) were classified as nonischemic, provided the most prognostic
power. A definition of ischemic cardiomyopathy that incorporated this definition had more
prognostic power than the traditional definition.
CONCLUSIONS Angiographically diagnosed ischemic HF is associated with shorter survival than nonischemic
HF. A more extensive CAD is independently associated with shorter survival, and patients
with single-vessel disease and no history of MI or revascularization should be classified as
nonischemic for prognostic purposes. Standardization of the definition of ischemic cardio-
myopathy will be useful in the conduct and interpretation of clinical research in HF. (J Am
Coll Cardiol 2002;39:210–8) © 2002 by the American College of Cardiology
Accurate prognostication is an important goal in the man-
agement of patients with chronic heart failure (HF), par-
ticularly given the limited availability of some therapies such
as cardiac transplantation. Among the most important
clinical determinants of prognosis in HF is the etiology of
left ventricular (LV) dysfunction. The last several decades
have seen a shift in the most common underlying etiology of
HF from hypertension and valvular disease to ischemic
heart disease (1). Ischemic etiology has been shown to be
independently associated with worse long-term outcome in
patients with LV dysfunction in a variety of studies (2–5).
The etiology of HF also impacts the decision to pursue
revascularization and may effect the response to some
pharmacologic therapies (6). Finally, recent data suggest
that the mechanism of sudden death may differ between
ischemic and nonischemic HF patients, further emphasiz-
ing the potential importance of accurate differentiation
between etiologies (7).
Clinically, patients are classified as having HF of ischemic
or nonischemic etiology based on a history of myocardial
infarction (MI) or based on objective evidence of coronary
artery disease (CAD) such as angiography or functional
testing. As a practical matter, however, the determination of
etiology in an individual patient may be difficult because
patients with HF and no CAD may have typical angina or
regional wall motion abnormalities on echocardiography
(8), whereas patients with severe CAD may have no
symptoms of angina or history of MI. This has lead to the
recommendation for either noninvasive functional testing or
coronary angiography in assessing patients with systolic
dysfunction, depending on the clinical presentation and risk
factor profile (9). Even with objective information such as
angiography, the appropriate classification for a given pa-
tient is not always clear. Although HF etiology represents
an important variable in the design and interpretation of
clinical trials (10), the means by which etiology was deter-
mined are often not clear from published reports, and
criteria may differ between studies (6). This may be of
particular importance in the design and interpretation of
clinical trials where etiology of HF is an important covariate
and frequently defines subgroups of interest. The lack of a
standardized definition of ischemic etiology may lead to
unnecessary variability in defining subgroups and inconsis-
tency between different studies. We sought to use data from
the Duke Databank for Cardiovascular Diseases to develop
the most prognostically powerful clinical definition of isch-
emic etiology.
METHODS
Data collection. Patient data was obtained from the Duke
Databank for Cardiovascular Diseases, an ongoing databank
of all patients undergoing diagnostic cardiac catheterization
at Duke University Medical Center. Patients were included
in the study population if they had an LV ejection fraction
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(EF) of40% and a history of symptomatic HF (New York
Heart Association [NYHA] functional class II or greater).
Patients were excluded from analysis if they had experienced
MI within 30 days of the index catheterization, had primary
valvular heart disease (defined as severe aortic or mitral
insufficiency or severe stenosis of any heart valve) or con-
genital heart disease. Baseline clinical variables for each
patient were stored in the Duke Databank using methods
previously described (11). Follow-up on patients with sig-
nificant coronary disease or revascularization procedures was
obtained through self-administered questionnaires, with
telephone follow-up to nonresponders. Patients not con-
tacted through this mechanism had vital status determined
through a search of the National Death Index (12).
Study definitions. Data from the index catheterization was
prospectively collected. Coronary stenoses were graded by
visual consensus of at least two experienced observers. In
order to determine the best method for quantifying the
angiographic data, several classification schemes were eval-
uated for their prognostic power. For the traditional binary
classification (ischemic vs. nonischemic), an ischemic etiol-
ogy of HF was defined as the presence of any epicardial
coronary vessels with75% stenosis or any history of MI or
coronary revascularization (either percutaneous transluminal
coronary angioplasty or coronary artery bypass grafting).
The number-of-diseased-vessels classification was defined
as the number of vessels with 75% stenosis (0, 1, 2 or 3).
The CAD prognostic index (see Appendix), which has been
previously described and validated in an overlapping HF
population (2), considers the number of diseased vessels, the
number of vessels with 95% stenosis and the presence of
left anterior descending (LAD) or left main coronary
disease. In addition, a modified binary definition of isch-
emic etiology was also evaluated, which reclassified those
patients with single-vessel disease who did not have a
history of MI or coronary revascularization into the non-
ischemic group. Patients with 75% stenosis of the left
main coronary artery or proximal LAD were included in the
ischemic group. This also led to a modified number-of-
diseased-vessels classification, wherein patients with single-
vessel disease were combined with those without any sig-
nificant coronary lesions (0/1, 2, 3). These modified
definitions attempted to define a group of patients with LV
dysfunction “out of proportion” to their degree of CAD.
Data analysis. This study sought to develop the definition
of ischemic etiology of HF that would provide the most
power to distinguish the differing prognoses between isch-
emic and nonischemic patients. In so doing, we compared
five classification schemes for assessing the extent of CAD:
the traditional binary classification (ischemic vs. nonisch-
emic), the number of diseased vessels (0, 1, 2, 3), the CAD
prognostic index, the modified binary classification and the
modified number-of-diseased-vessels classification (0/1, 2, 3).
Statistical analysis. Baseline characteristics are described
with medians and interquartile ranges for continuous vari-
ables and percentages for discrete variables. Pearson chi-
square tests were used for group comparisons of unordered
categorical variables, and Kruskal-Wallis tests were used for
continuous measures. Survival curves for various groups
were constructed using the method of Kaplan and Meier,
and comparisons were made using the log-rank test. A p
value 0.05 was used to indicate statistical significance for
all comparisons. The association between baseline charac-
teristics and mortality was calculated using a Cox propor-
tional hazards model. Increased risk associated with a given
variable was described using hazard ratios, which gives the
relative increase in risk associated with the presence of a
given characteristic. Multivariable Cox proportional hazards
analysis was used to adjust for baseline differences between
groups. The overall prognostic power of a given model was
assessed by comparing the overall log likelihood ratio
Table 1. Baseline Characteristics
Characteristics
Ischemic
(n  1,304)
(%)
Nonischemic
(n  617)
(%)
p
Value
Gender (male) 71.2 54.1 0.001
Age 64 (56, 71) 55 (45, 65) 0.001
Race (Caucasian) 78.3 55.7 0.001
Hypertension 65.6 56.6 0.001
NYHA class
II 29.7 20.7 0.001
III 39.3 41.7
IV 31.0 37.6
Hx angina 79.1 40.2 0.001
Diabetes mellitus 40.6 21.1 0.001
Mitral regurgitation 46.8 48.2 0.154
Hx cerebrovascular disease 17.0 7.0 0.001
Hx PVD 21.4 3.9 0.001
Hx COPD 11.2 7.0 0.004
Hx renal disease 4.2 2.1 0.019
Hyperlipidemia 47.2 20.8 0.001
Smoking 68.6 51.1 0.001
Carotid bruits 14.4 2.3 0.001
Ventricular gallop 25.4 35.6 0.001
Ejection fraction 28 (22, 34) 25 (19, 32) 0.001
# of diseased vessels
0 6.4 100
1 22.2 —
2 24.2 —
3 47.2 —
Hx revascularization 34.6
Hx  history of; PVD  peripheral vascular disease; COPD  chronic obstructive
pulmonary disease; NYHA  New York Heart Association.
Abbreviations and Acronyms
CAD  coronary artery disease
EF  ejection fraction
HF  heart failure
LAD  left anterior descending coronary artery
LV  left ventricle, left ventricular
MI  myocardial infarction
NYHA  New York Heart Association
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chi-square value for each model. The best definition of
ischemic cardiomyopathy was considered to be the defini-
tion that maximized the chi-square test statistic for the
model. All statistical analysis was performed with SAS
version 6.1 (SAS Institute, Cary, North Carolina).
RESULTS
A total of 1,921 patients met criteria for the study between
January 1, 1986, and December 31, 1999. Median follow-up
for the cohort was 3.1 years (interquartile range 1.0 to 6.2).
Baseline characteristics. Baseline characteristics for the
ischemic and nonischemic groups are provided in Table 1.
Using the traditional definition of ischemic etiology, 1,304
patients (68%) were classified as ischemic and 617 (32%) as
nonischemic. As expected, a number of baseline character-
istics differed significantly between the ischemic and non-
ischemic cohorts, with ischemic patients more likely to be
older, male, Caucasian, hypertensive, diabetic and smokers.
Figure 1. Unadjusted Kaplan-Meier survival curves for ischemic versus nonischemic patients.
Table 2. Univariable Relation of Baseline Characteristics
With Mortality
Characteristics Chi-Square
p
Value
Hazard
Ratio
Age (10 yr increments) 143.3 0.0001 1.400
Men 7.0 0.0081 1.201
Race: white 1.0 0.3106 1.078
Ejection fraction (5 U increments) 24.3 0.0001 0.907
Mitral regurgitation 14.5 0.0001 1.163
Vascular disease (PVD, CRV, bruits) 28.1 0.0001 1.446
Hx hypertension 5.4 0.0203 1.167
NYHA functional class 9.7 0.0019 1.137
Diabetes 27.4 0.0001 1.424
Hx angina 5.9 0.0150 1.183
Hx revascularization 0.1 0.8206 0.983
Valvular disease 20.2 0.0001 1.338
Ischemia variable
Ischemic 54.7 0.0001 1.755
Number diseased vessels 98.0 0.0001 1.295
CAD index (per 10 U) 87.0 0.0001 1.111
Modified ischemic 56.8 0.0001 1.688
Modified number diseased vessels 91.1 0.0001 1.406
CAD  coronary artery disease; CRV  cerebrovascular disease; Hx  history of;
NYHA  New York Heart Association; PVD  peripheral vascular disease.
Table 3. Comparison of Prognostic Power of
Multivariable Models
Model
Model
Chi-Square
Baseline characteristics only (no measure of CAD
included)
241.8
Traditional binary ischemia classification 256.5
CAD index 273.4
Traditional number-of-diseased-vessels classification
(0, 1, 2, 3)
283.2
Modified binary ischemia classification 267.5
Modified number-of-diseased-vessels classification
(0/1, 2, 3)
286.5
Each model adjusts for age, gender, ejection fraction, NYHA functional class,
diabetes mellitus and valvular disease; degrees of freedom  6 for baseline charac-
teristics model, degrees of freedom  7 for all other models.
CAD  coronary artery disease; NYHA  New York Heart Association.
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Figure 2. Adjusted survival curves for each of the five methods of quantifying coronary artery disease (CAD). All curves additionally adjusted for age,
ejection fraction, gender, New York Heart Association functional class, diabetes mellitus and valvular heart disease. (A) Traditional binary classification.
(B) Modified binary classification. (C) CAD index. (D) Number-of-diseased-vessels classification. (E) Modified number-of-diseased-vessels classification.
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Figure 2. Continued.
214 Felker et al. JACC Vol. 39, No. 2, 2002
Definition of Ischemic Cardiomyopathy January 16, 2002:210–8
Ejection fraction was slightly higher in the ischemic cohort
than it was in the nonischemic cohort. Notably, over 40% of
patients classified as nonischemic based on angiography
reported a history of anginal chest pain.
Survival. Overall five-year survival for the study population
was 49%. As expected, patients with an ischemic etiology of
HF had shorter survival than those with nonischemic HF
(five-year survival: 45% for the ischemic group vs. 62% for
the nonischemic group, p  0.001 by log-rank test).
Unadjusted survival curves for the two groups are shown in
Figure 1. Using unadjusted Cox proportional hazards anal-
ysis, a greater extent of CAD was significantly associated
with shorter survival regardless of the classification scheme
used. Unadjusted relationships between all tested variables
and survival are shown in Table 2.
Multivariable analysis. Variables that were significant in
the unadjusted analysis or thought to have clinical relevance
were included as candidates in a multivariable survival
model. After adjustment for baseline characteristics, isch-
emic etiology remained a significant independent predictor
of long-term survival. Other independent predictors of
survival were increasing age, male gender, lower EF, in-
creasing NYHA functional class, diabetes mellitus and
valvular heart disease.
Comparing etiology classification schemes. In order to
assess the most prognostically powerful method for describ-
ing ischemic etiology, several models were compared. Each
model included the independent baseline predictors of
survival (age, gender, EF, NYHA functional class, diabetes
and valvular heart disease) while varying the etiology clas-
sification scheme. Etiology remained independently associ-
ated with outcome regardless of which classification scheme
was used. The log likelihood ratio chi-squares for each
overall model are provided in Table 3, and adjusted survival
curves for each of the five methods of classifying ischemia
are shown in Figure 2. The modified number-of-diseased-
vessels model (zero to one-, two- or three-vessel disease)
provided the best prognostic power overall. Among the
binary classification models, the modified definition of
ischemic etiology provided an increase in the prognostic
power of the model (as measured by the overall model
chi-square) over the traditional definition. Hazard ratios for
Figure 2. Continued.
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each of the independent predictors of outcome are shown in
Figure 3.
DISCUSSION
The association of extent of CAD in a large population with
both symptomatic and asymptomatic LV dysfunction has
been previous reported by Bart et al. (2). That study
demonstrated that the extent of CAD provides improved
prognostic power over a binary definition in patients with
LV dysfunction, with or without the clinical syndrome of
HF. The current study examines those relationships in a
more clinically applicable population with symptomatic HF
(NYHA functional class II or greater), evaluating a large
cohort of such patients with up to 14 years of follow-up. In
so doing, we sought to develop and assess a more prognos-
tically accurate definition of ischemic etiology that could be
used for classification of HF patients in population studies
and clinical trials, where etiology of HF is an important
variable with substantial prognostic and therapeutic impli-
cations.
Our study identified a population of patients who would
have traditionally been classified as having an ischemic
etiology of HF but who had a prognosis similar to those
with nonischemic etiology. These patients, who had single-
vessel disease but no history of revascularization or MI,
represent patients with HF “out or proportion” to their
degree of CAD. Of the 1,304 patients initially classified as
ischemic, 140 (11%) were reclassified into the nonischemic
category based on this definition. By reclassifying such
patients into the nonischemic group, we added prognostic
power to the binary classification model and the more
detailed number-of-diseased-vessels model. Since a binary
classification system remains attractive due to its simplicity,
we propose a modified definition of ischemic etiology of HF
that includes patients with single-vessel coronary disease
only if present in the left main or proximal LAD artery in
patients without a history of MI or prior revascularization
(Table 4).
Figure 3. Hazard ratios and 95% confidence intervals for all independent predictors of survival in the best multivariable model (modified number-of-
diseased-vessels model). CHF  congestive heart failure; dz  diseased; EF  ejection fraction.
Table 4. Proposed Definition of Ischemic Cardiomyopathy
Patients with history of MI or revascularization (CABG or PCI)
Patients with 75% stenosis of left main or proximal LAD
Patients with 75% stenosis of two or more epicardial vessels
CABG  coronary artery bypass grafting; LAD  left anterior descending coronary
artery; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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Assigning etiology of HF. Although the accurate assess-
ment of the etiology of HF may be obvious in many cases,
it may be a difficult clinical problem in others. Clinicians
may use varying definitions or criteria to assign etiology,
resulting in heterogeneity in clinical research as well as
clinical practice. Our data point out the difficulty of using
clinical assessment for this purpose, as 40% of the patients
in the nonischemic group reported a history of typical
angina. Quantification of coronary disease by angiography
remains the most definitive means for assessing both the
presence and the extent of CAD. Although a specific
histologic pattern (replacement fibrosis) has been reported
in endomyocardial biopsy specimens of patients with isch-
emic cardiomyopathy, this method lacks sensitivity and is
significantly invasive (13). Traditional noninvasive means,
such as nuclear imaging and echocardiography, have not
been shown to consistently differentiate ischemic from
nonischemic HF patients (14,15). Novel noninvasive means
for differentiating ischemic and nonischemic cardiomyopa-
thy such as positron emission tomography and electron-
beam computed tomography are under investigation but not
yet validated (16,17). Despite the potential attractiveness of
noninvasive testing, our data suggest that detailed assess-
ment of the extent of CAD, as can be done only with
angiography, can contribute additional prognostic data in
patients with symptomatic HF.
Study limitations. The current study has several limita-
tions. The study cohort was taken from the Duke Databank
for Cardiovascular Disease, which contains data only on
patients undergoing diagnostic cardiac catheterization.
Thus, patients in both the ischemic and nonischemic groups
would be weighted toward those with a higher “index of
suspicion” for CAD. Although patients thought to be at
very low risk for CAD would have been excluded from this
analysis, our study population does reflect the patient
population in which decision-making about etiology of HF
is most difficult. Additionally, the pathophysiology of HF is
complex, and many pathologic processes (such as ischemia,
hypertension and diabetes mellitus) may contribute to the
development of LV dysfunction in a given patient. Al-
though binary classification systems are attractive due to
simplicity and clarity, they may represent an oversimplifi-
cation of a complex biologic phenomenon. Our study is
strengthened by the requirement of coronary angiography in
all patients, the large cohort of patients and the long-term
follow-up.
Conclusions. We propose a new definition of ischemic
cardiomyopathy that reclassifies patients with single-vessel
disease as nonischemic unless they have left main or
proximal LAD disease or a history of revascularization or
MI. The use of such a standardized definition will help limit
variability in defining etiologic subgroups for clinical trials
and population-based studies. Accurate ascertainment of
etiology and its impact on prognosis is important for risk
stratification of individual patients and for planning appro-
priate subgroups for clinical research. Based on these data,
coronary angiography should remain a cornerstone of the
evaluation of patients with newly diagnosed systolic dys-
function and symptomatic HF.
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APPENDIX
The Coronary Artery Disease (CAD) Index
The CAD prognostic index is a hierarchical scoring system to describe
the extent of CAD on a continuous scale from 1 to 100
Extent of CAD
Prognostic Weight
(0 to 100)
No CAD 50% 0
One-VD 50% to 74% 19
One-VD 50% to 74% 23
One-VD 75% 23
One-VD  95% 32
Two-VD 37
Two-VD (both  95%) 42
One-VD  95%, proximal (LAD) 48
Two-VD  95% LAD 48
Two-VD  95% proximal LAD 56
Three-VD 56
Three-VD  95% in at least one vessel 63
Three-VD 75% proximal LAD 67
Three-VD  95% proximal LAD 74
Left main (75%) 82
Left main (95%) 100
CAD  coronary artery disease; LAD  left anterior descending coronary artery;
VD  vessel disease.
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